All In Biotech

Drug Trial Radar · NCT07557407

A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male Subjects

An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]HRS-1780 After a Single Oral Dose to Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

May 2026

Primary completion

Jun 2026

Study completion Jun 2026

Sponsor

Sponsor type
Industry
First posted
Apr 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study aims to evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of \[14C\]HRS-1780 following an oral single dose in healthy adult male participants.

Conditions

  • Chronic Kidney Diseases

Interventions

  • [14C]HRS-1780Drug

    \[14C\]HRS-1780, oral.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total radioactivity ratio of whole blood/plasma.Time frame: 0 to anticipated 11 days.
  2. TmaxTime frame: 0 to anticipated 11 days.
  3. CmaxTime frame: 0 to anticipated 11 days.
  4. AUClastTime frame: 0 to anticipated 11 days.
  5. AUC0-infTime frame: 0 to anticipated 11 days.
  6. t1/2Time frame: 0 to anticipated 11 days.
  7. CL/FTime frame: 0 to anticipated 11 days.
  8. Vz/FTime frame: 0 to anticipated 11 days.
  9. %AUCTime frame: 0 to anticipated 11 days.
  10. %DoseTime frame: 0 to anticipated 11 days.
  11. Total radioactivity ratio for blood/plasma.Time frame: 0 to anticipated 11 days.
  12. The cumulative recovery amount and recovery rate of total radioactive substances in urine and feces.Time frame: 0 to anticipated 11 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jinan Central Hospital, Affiliated to Shandong First Medical University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.